Stifel Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $35
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and sets a price target of $35.
July 02, 2024 | 9:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Paul Matteis has initiated coverage on Rapport Therapeutics with a Buy rating and a price target of $35. This positive analyst rating and price target could boost investor confidence and potentially drive the stock price up in the short term.
The initiation of coverage with a Buy rating and a specific price target of $35 by a reputable analyst from Stifel is likely to positively influence investor sentiment. This could lead to increased buying activity and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100